{
    "clinical_study": {
        "@rank": "58618", 
        "acronym": "MIRACLE I", 
        "arm_group": {
            "arm_group_label": "DEB-TACE", 
            "arm_group_type": "Other", 
            "description": "Transarterial Chemoembolization with TANDEM\u2122 - DOX Microspheres (DEB-TACE)\nTreatment: Lobes;                                                   Dosing: TANDEM\u2122/Doxorubicin; Second Treatment:TANDEM\u2122/Doxorubicin"
        }, 
        "brief_summary": {
            "textblock": "This is a non-randomized, prospective, pilot, Multicenter Study of DEB-TACE using\n      Doxorubicin-Loaded Embozene\u00ae Tandem\u2122 Microspheres to treat HCC."
        }, 
        "brief_title": "Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with a confirmed diagnosis of HCC according to the EASL criteria for\n             diagnosis, and staged according to the BCLC criteria\n\n          2. Subject is competent and willing to provide written informed consent in order to\n             participate in the study\n\n          3. Adults (male or female) patients \u2265 18 years of age\n\n          4. ECOG performance status 0-2 or Child Pugh classification is 0-11\n\n          5. Multidonar or single nodular tumor \u22653-10cm, Patients with bilobar disease who can be\n             treated superselectively in a single session or both lobes able to be treated within\n             3-5 weeks. Patient must have at least one tumor lesion that meets the following\n             criteria: Lesion can be accurately measured in at least one dimension according to\n             mRECIST criteria\n\n          6. No invasion in the major blood vessel (hepatic portal, hepatic vein) or bile duct by\n             the MRI or CT\n\n          7. Proper blood, liver, renal, heart function: testing result within 2 weeks from\n             registry of this study\n\n          8. No current infections requiring antibiotic therapy\n\n          9. Not actively on cumarin based anticoagulation or suffering from a known bleeding\n             disorder\n\n         10. Measurable disease per the Response Evaluation Criteria in Solid Tumors (mRECIST)\n\n         11. Expected survival  more than 6 months\n\n        Exclusion Criteria:\n\n          1. ECOG performance status >2; or Child-Pugh class C11 or more, or ASA class 5\n\n          2. Bilirubin levels >3 mg/dl\n\n          3. HCC with large vessel or biliary duct invasion, diffuse HCC or extrahepatic spread\n\n          4. Patients in which any of the following are contraindicated or present:\n\n               -  The use of doxorubicin\n\n               -  MRI\n\n               -  Hepatic embolization procedures\n\n               -  WBC < 3000 cells/mm3\n\n               -  neutrophil < 1500 cells/mm3\n\n               -  Cardiac ejection fraction < 50 percent assessed by isotopic ventriculography,\n                  echocardiography or MR\n\n               -  Elevated creatinine greater than or equal to 2.5 mg/dl\n\n               -  Impaired clotting test (platelet count < 5 x 104/mm3, PT-INR > 2.0)\n\n               -  AST and/or ALT >5x ULN or, when greater >250 U/L\n\n               -  Known hepatofugal blood flow\n\n               -  Arterio-venous shunt\n\n               -  Arterio-portal shunt\n\n               -  Main stem portal vein occlusion(point 6 in inclusion criteria)\n\n          5. Women who are pregnant or breast feeding\n\n          6. Allergy to iodinated contrast used for angiography\n\n          7. Tumour burden of more than 50% of liver\n\n          8. Patients with objective signs of active bacterial, viral (HIV),  or fungal infection\n\n          9. Other primary malignancies or evidence of metastatic disease\n\n         10. Patients previously treated with anthracyclines (other than doxorubicin).\n\n         11. Any co-morbid disease or condition or event that, in the investigator's judgment,\n             would place the patient at undue risk that would preclude the safe use of DEB-TACE.\n\n         12. Under no circumstances should patients be enrolled in this study who is already\n             participating in another study for treatment of primary liver cancer.\n\n         13. Under no circumstances should patients be enrolled in this study who has received any\n             other embolotherapy (including SIRT) for the treatment of primary liver cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798134", 
            "org_study_id": "TANDEM 2012-001 OUS"
        }, 
        "intervention": {
            "arm_group_label": "DEB-TACE", 
            "intervention_name": "TANDEM\u2122", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "To show safety", 
            "and efficacy", 
            "investigational product"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Anne Schmitz", 
                    "phone": "0049 622 156 35667"
                }, 
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "69120"
                    }, 
                    "name": "Klinikum der Universitat Heidelberg"
                }, 
                "investigator": {
                    "last_name": "Ulrike Stampfl", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Josef Huber", 
                    "phone": "0049 713 149 3800"
                }, 
                "facility": {
                    "address": {
                        "city": "Heilbronn", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "74078"
                    }, 
                    "name": "SLK-Kliniken Heilbronn GmbH"
                }, 
                "investigator": {
                    "last_name": "Philippe Pereira", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jenny SEIDEL", 
                    "phone": "0049 711 278 34415"
                }, 
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "70174"
                    }, 
                    "name": "Klinikum Stuttgart- Katharinenhospital"
                }, 
                "investigator": {
                    "last_name": "Gotz M Richter", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Manuela Schweinhuber", 
                    "phone": "0049 899 270 2201"
                }, 
                "facility": {
                    "address": {
                        "city": "Munchen", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "81925"
                    }, 
                    "name": "Klinikum Bogenhausen"
                }, 
                "investigator": {
                    "last_name": "Thomas Helmberger", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alexander Steinmetz", 
                    "phone": "0049 615 110 76771"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "64283"
                    }, 
                    "name": "Kilinikum Darmstadt"
                }, 
                "investigator": {
                    "last_name": "Peter Huppert", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Thore Brink", 
                    "phone": "0049 201 723 85509"
                }, 
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "45147"
                    }, 
                    "name": "Universitatsklinikum Essen"
                }, 
                "investigator": {
                    "last_name": "Jens Christian Altenbernd", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simone Frankl", 
                    "phone": "0049 941 944 7431"
                }, 
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "zip": "93042"
                    }, 
                    "name": "University Hospital Regensburg"
                }, 
                "investigator": {
                    "last_name": "Christian Stroszcynski", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "edemant-bauchspiess@celonova.com", 
            "last_name": "Elisabeth Demant-Bauchspiess", 
            "phone": "+49 0 7319331140"
        }, 
        "overall_contact_backup": {
            "email": "jhart@celonova.com", 
            "last_name": "Jane Hart", 
            "phone": "210-489-4025"
        }, 
        "overall_official": {
            "affiliation": "Klinikum Stuttgart - Katharinenhospital", 
            "last_name": "Gotz M Richter, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\u2022 Study Efficacy Goals:\nFreedom of primary tumor progression at 6 months (EASL and mRECIST)\nAverage time to progression in all patients", 
                "measure": "Number of Patients with SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Tumor Progression", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798134"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary objectives include:\nLocal tumor control based on the devascularization pattern.  If any patient is referred to liver transplantation: Local tumor control based on microscopic analysis\n12 month survival", 
            "measure": "Local Tumor control", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "CeloNova BioSciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CeloNova BioSciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}